source
- Novo and Pfizer appoint new CFOs while Alnylam sees departure of its chief commercial officerNovo announced the appointment of a new chief financial officer as part of its effort to improve financial leadership. The hire follows earlier reports that the company is seeking to turn a corner…
- RevMed's pancreatic cancer drug Rasonque generates $198M in Q3, far exceeding forecastsRevMed reported $198 million in revenue from its newly launched pancreatic cancer therapy Rasonque during the third quarter, roughly ten times the $19 million estimate from Truist Securities. The…